Risk stratification and potential overtreatment in adjuvant CDK4/6 inhibitor trials: do all patients with Stage II disease and favorable biology derive benefit?

European Journal of Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles